本文選題：子宮內(nèi)膜癌 + 抑癌基因�。� 參考：《山東醫(yī)藥》2017年45期

【摘要】：目的探討Elf5在子宮內(nèi)膜癌組織中的表達(dá)情況及其臨床意義。方法選取子宮內(nèi)膜癌組織84例份、子宮內(nèi)膜不典型增生組織30例份和正常子宮內(nèi)膜組織30例份,用免疫組化法檢測Elf5在不同內(nèi)膜組織中的表達(dá)情況,分析其與子宮內(nèi)膜癌患者各臨床病理指標(biāo)的相關(guān)性;對所有子宮內(nèi)膜癌患者進(jìn)行術(shù)后隨訪,采用KaplanMeier進(jìn)行生存分析,Cox比例風(fēng)險(xiǎn)回歸模型進(jìn)行子宮內(nèi)膜癌多因素分析。結(jié)果 (1)子宮內(nèi)膜癌組織Elf5陽性表達(dá)率低于正常子宮內(nèi)膜組織及不典型增生子宮內(nèi)膜組織(χ2分別為5.787、1.614,P均0.05);(2)Elf5的表達(dá)與FIGO分期、病理分級、病理類型、淋巴結(jié)轉(zhuǎn)移和肌層浸潤深度有關(guān)(P均0.05);(3)Kaplan-Meier生存分析顯示,Elf5陰性表達(dá)患者的平均生存時(shí)間短于陽性表達(dá)患者(P0.05);(4)Cox回歸分析顯示FIGO分期、病理分級、肌層浸潤深度、淋巴結(jié)轉(zhuǎn)移及Elf5與子宮內(nèi)膜癌患者預(yù)后有關(guān)(P均0.05),其中Elf5是子宮內(nèi)膜癌患者預(yù)后的獨(dú)立危險(xiǎn)因素(P0.05)。結(jié)論子宮內(nèi)膜癌組織中Elf5表達(dá)降低,其水平降低與子宮內(nèi)膜癌發(fā)生發(fā)展及預(yù)后相關(guān)。
[Abstract]:Objective to investigate the expression of Elf5 in endometrial carcinoma and its clinical significance.Methods 84 cases of endometrial carcinoma, 30 cases of endometrial atypical hyperplasia and 30 cases of normal endometrium were selected to detect the expression of Elf5 in different endometrial tissues by immunohistochemistry.To analyze its correlation with the clinicopathological parameters of endometrial carcinoma, to follow up all patients with endometrial carcinoma after operation, and to analyze the multivariate factors of endometrial carcinoma by KaplanMeier survival analysis and Cox proportional risk regression model.Results (1) the positive expression rate of Elf5 in endometrial carcinoma was lower than that in normal endometrium and atypical hyperplasia endometrium (蠂 ~ 2 = 5.7871.614P, respectively). The expression of Elf5 in endometrial carcinoma was lower than that in normal endometrial tissue and atypical hyperplasia endometrium (蠂 ~ 2 = 0.05). The expression of Elf5 in endometrial carcinoma was correlated with FIGO stage, pathological grade and pathological type.The results of Kaplan-Meier survival analysis showed that the mean survival time of the patients with negative expression of Elf5 was shorter than that of the patients with positive expression (P 0.05). The regression analysis showed FIGO staging, pathological grade and depth of myometrial invasion.Lymph node metastasis and Elf5 were associated with prognosis in patients with endometrial carcinoma (P 0.05). Elf5 was an independent risk factor for the prognosis of endometrial carcinoma.Conclusion the decrease of Elf5 expression in endometrial carcinoma is related to the development and prognosis of endometrial carcinoma.
【作者單位】： 徐州醫(yī)科大學(xué)研究生學(xué)院;徐州醫(yī)科大學(xué)附屬醫(yī)院;
【分類號】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 李桃;蔡晶;王澤華;;子宮內(nèi)膜癌淋巴結(jié)轉(zhuǎn)移的術(shù)前評估[J];婦產(chǎn)與遺傳(電子版);2014年01期

相關(guān)博士學(xué)位論文 前3條

1 張燕;年輕子宮內(nèi)膜癌及不典型增生患者孕激素保留生育功能治療的療效及妊娠分析[D];天津醫(yī)科大學(xué);2017年

2 劉彩艷;子宮內(nèi)膜癌淋巴結(jié)轉(zhuǎn)移的風(fēng)險(xiǎn)評估及淋巴管生成的相關(guān)研究[D];天津醫(yī)科大學(xué);2017年

3 高超;IK基因的失活性突變及其蛋白缺失在子宮內(nèi)膜癌中的作用研究[D];天津醫(yī)科大學(xué);2017年

相關(guān)碩士學(xué)位論文 前1條

1 凡亞運(yùn);絕經(jīng)后子宮內(nèi)膜癌高危因素及術(shù)后病理分析[D];寧夏醫(yī)科大學(xué);2017年

，

本文編號：1747643